Hanger Announces Financial Results for the First Quarter of 2019

Net revenue was $236.4 million for the three months ended March 31, 2019, compared to $234.0 million for the same period in 2018, reflecting a net revenue increase of 1.0 percent year-over-year.

Logo
May 8, 2019 20:10 UTC
 

AUSTIN, Texas--(BUSINESS WIRE)-- Hanger Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the first quarter ended March 31, 2019.

Financial Highlights for the First Quarter of 2019

  • Net revenue was $236.4 million for the three months ended March 31, 2019, compared to $234.0 million for the same period in 2018, reflecting a net revenue increase of 1.0 percent year-over-year.
  • GAAP net loss totaled $7.0 million for the three months ended March 31, 2019, compared to a net loss of $22.6 million for the same period in 2018. The net loss in the first quarter of 2018 included the impact of a $17.0 million pre-tax loss on the extinguishment of debt as well as higher interest expense compared to the first quarter of 2019.
  • GAAP loss from operations totaled $2.0 million for the three months ended March 31, 2019, compared to income from operations of $0.6 million for the same period in 2018.
  • Adjusted EBITDA was $11.9 million in the first quarter of 2019, compared to $16.2 million for the same period in 2018, reflecting a decrease of $4.3 million. The decline in Adjusted EBITDA was driven primarily by expected increases of $1.8 million in benefits expense and $1.0 million in rent expense, as well as expected lower margins within the Products and Services segment.
  • GAAP loss per share was ($0.19) for the first quarter of 2019, compared to a loss per share of ($0.62) for the same period in 2018. The reduction in GAAP loss per share related primarily to the prior year refinancing costs, a reduction in interest expense and lower third party professional fees.
  • Adjusted diluted loss per share was ($0.16) for the three months ended March 31, 2019, compared to loss per share of ($0.13) for the same period in 2018.
  • The Company reaffirmed its 2019 financial outlook (see "2019 Outlook" within this release).

Vinit Asar, President and Chief Executive Officer of Hanger, Inc., stated, "While revenue growth in the quarter was below our expectations, we believe this relates primarily to the timing of our prosthetics deliveries. As a result, we are reaffirming both our revenue and earnings guidance for 2019. We remain positive in our view of the demand for our O&P services, strength in our referrals patterns, and the overall industry fundamentals."

Complete reconciliations of GAAP to non-GAAP financial measures are provided in the tables located at the end of this press release.

Segment Results for Three Months Ended March 31, 2019

Patient Care Segment

For the three months ended March 31, 2019, Patient Care net revenue was $190.6 million, an increase of $2.1 million or 1.1 percent, compared to the same period in 2018. Growth on a reported basis was attributed to $4.8 million of revenue during the quarter from O&P clinics acquired in late 2018 and early 2019.

After adjusting for one less revenue day in the first quarter, same clinic revenue for the three months ended March 31, 2019 was consistent with the prior year period. Revenue from prosthetic services decreased 0.7 percent on a day-adjusted basis compared to the prior year and revenue from orthotics increased by 0.9 percent on a day-adjusted basis.

Income from operations in the Patient Care segment was $15.8 million during the first quarter of 2019, which reflected a $1.3 million decline, compared to $17.1 million reported in the prior year. Adjusted EBITDA for the segment was $21.4 million, which reflected a $1.6 million or 7.0 percent decline compared to the $23.0 million reported in the prior year period. Results reflected higher health benefit and rent expenses as compared with the prior year period, with the Patient Care segment bearing $1.5 million of the Company's $1.8 million increase in benefits costs and $0.9 million of the $1.0 million total increase in rent expense. Benefits costs are inherently volatile from one period to the next as they are dependent on the Company's underlying claim experience, which was favorable in the first quarter of 2018. Of the total rent increase, $0.3 million related to the adoption of the new lease accounting standard, Accounting Standards Codification (ASC) 842, and the remainder of the increase related to rent increases and completed acquisitions.

Products & Services Segment

For the three months ended March 31, 2019, Products & Services net revenue totaled $45.8 million, which reflected a $0.3 million, or 0.7 percent increase compared to the same period in 2018. Revenue growth was driven by a $1.8 million, or 5.9 percent increase from the distribution of O&P componentry to independent providers, which was partially offset by a $1.5 million decrease in revenue from therapeutic solutions.

Income from operations for the Products & Services segment decreased by $1.8 million to $4.1 million in the first quarter of 2019 compared to the same period in 2018. Adjusted EBITDA for the Products & Services segment was $6.9 million for the first quarter of 2019, which reflected a $1.8 million decrease compared with the same period of 2018. The decline in therapeutic solutions revenue as well as lower margins within O&P distribution impacted segment earnings in the quarter.

Corporate & Other

The loss from operations relating to corporate and other activities decreased by $0.5 million to $21.8 million for the quarter ended March 31, 2019 compared to the same period in 2018. This decrease primarily related to a $2.1 million reduction in professional accounting and legal fees year-over-year. Excluding the effect of excess third party professional fees, depreciation and amortization, certain acquisition related transaction costs and non-cash equity compensation expense, the net cost of corporate and other activities increased by $1.0 million to $16.4 million in the first quarter of 2019. Increases in costs for Corporate & Other activities related primarily to initial planning for the implementation of new financial and supply chain systems as well as an increase in compensation costs, franchise tax expense and other tax-related costs.

Net Income; Interest Expense

For the three months ended March 31, 2019, net loss was $7.0 million compared with a net loss of $22.6 million in the same period in 2018. The $15.7 million improvement in net income year-over-year was due primarily to a $17.0 million pre-tax loss on the extinguishment of debt associated with the 2018 debt refinancing as well as decreases in interest expense.

Liquidity

On March 31, 2019, the Company had liquidity of $115.3 million, comprised of $20.5 million in cash and cash equivalents, and $94.8 million in available borrowing capacity under its revolving credit facility, compared to liquidity of $189.2 million on December 31, 2018.

The decrease in liquidity was primarily attributable to the use of $36.5 million for the payment of annual incentive bonuses, tax payments on stock vesting, and the employer 401(k) matching contribution, the use of $27.7 million for an acquisition closed in the first quarter, and a $5.6 million net reduction in accounts payable.

2019 Outlook

Hanger reaffirms its full-year 2019 net revenue and Adjusted EBITDA outlook as follows:

Revenue in a range between $1.075 billion and $1.105 billion, and Adjusted EBITDA in a range between $121 million and $126 million.

Hanger's financial outlook for 2019 does not incorporate contributions from potential future acquisitions. Adjusted EBITDA is provided on a non-GAAP basis only because a reconciliation to the most comparable GAAP financial measure, net income, is not available without unreasonable effort due to the unpredictable nature of reconciling items that render such a reconciliation not meaningful for investors.

Conference and Webcast Details

Hanger’s management team will host a conference call tomorrow, Thursday, May 9, at 8:30 a.m. Eastern time to discuss the Company’s first quarter 2019 financial results and business outlook.

To participate, dial 877-407-6184 or 201-389-0877 outside the U.S. and Canada, and use conference code number 13689515. A live webcast and replay of the call will be available at the Investor Relations section of the Company’s web site at https://investor.hanger.com/events/conferences-and-corporate-access/default.aspx, and a replay of the webcast will remain available for one year.

Additional Notes

A reconciliation of GAAP and non-GAAP financial results is included in the tables provided at the back of this press release. The Company has provided certain supplemental key statistics relating to its results for certain prior periods. These key statistics are non-GAAP measures used by the Company’s management to analyze the Company’s business results that are being provided for informational and analytical context.

Accompanying supplemental information will be posted to the Investor Relations section of Hanger’s web site at www.hanger.com/investors.

About Hanger, Inc. – Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HNGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions. Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics with approximately 800 patient care locations nationwide. Through its Products & Services segment, Hanger distributes O&P devices, products and components, and provides rehabilitative solutions. With over 150 years of clinical excellence and innovation, Hanger's vision is to lead the orthotic & prosthetic markets by providing superior patient care, outcomes, services and value. For more information on Hanger, visit www.hanger.com.

This press release contains certain “forward-looking statements” relating to the Company. All statements, other than statements of historical fact included herein, are “forward looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “preliminary,” “intends,” “expects,” “plans,” “anticipates,” “believes,” “views” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. These uncertainties include, but are not limited to, the risk of our identified material weaknesses in the Company’s internal control over financial reporting adversely affecting its ability to report its financial condition and results of operations in a timely and accurate manner; any litigation relating to the Company’s accounting practices, financial statements and other financial data, periodic reports or other corporate actions; changes in the demand for the Company’s O&P products and services; uncertainties relating to the results of operations or recently acquired O&P patient care clinics; the Company’s ability to enter into and derive benefits from managed-care contracts; the Company’s ability to successfully attract and retain qualified O&P clinicians; federal laws governing the health care industry; uncertainties inherent in investigations and legal proceedings; governmental policies affecting O&P operations; and other risks and uncertainties generally affecting the health care industry. For additional information and risk factors that could affect the Company, see its Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission. The information contained in this press release is made only as of the date hereof, even if subsequently made available by the Company on its website or otherwise.

       
       
Table 1
Hanger, Inc.
Condensed Consolidated Statements of Operations

(Unaudited - dollars in thousands, except share and per share amounts)

       
      For the Three Months Ended
March 31,
      2019     2018
Net revenues     $ 236,419       $ 233,995  
Material costs       78,377         76,356  
Personnel costs       86,711         86,108  
Other operating costs       33,555         31,096  
General and administrative expenses       28,282         25,636  
Professional accounting and legal fees       2,700         4,846  
Depreciation and amortization       8,773         9,330  
(Loss) income from operations       (1,979 )       623  
Interest expense, net       8,538         12,263  
Loss on extinguishment of debt               16,998  
Non-service defined benefit plan expense       173         176  
Loss before income taxes       (10,690 )       (28,814 )
Benefit for income taxes       (3,739 )       (6,196 )
Net loss     $ (6,951 )     $ (22,618 )
             
Basic and Diluted Per Common Share Data:            
Basic and diluted loss per share     $ (0.19 )     $ (0.62 )
Weighted average shares used to compute basic and diluted earnings per common share       37,001,977         36,498,482  
                     
             
Table 2
Hanger, Inc.
Condensed Consolidated Balance Sheets

(Unaudited - dollars in thousands)

             
      As of March 31,     As of December 31,
      2019     2018
ASSETS            
Current assets:            
Cash and cash equivalents     $ 20,511       $ 95,114  
Accounts receivable, net       136,891         143,986  
Inventories       70,036         67,690  
Income taxes receivable       734         379  
Other current assets       17,058         18,731  
Total current assets       245,230         325,900  
Non-current assets:            
Property, plant and equipment, net       81,951         89,489  
Goodwill       226,632         198,742  
Other intangible assets, net       16,415         15,478  
Deferred income taxes       69,738         65,635  
Operating lease right-of-use assets       103,676          
Other assets       8,392         7,766  
Total assets     $ 752,034       $ 703,010  
             
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT      
Current liabilities:            
Current portion of long-term debt     $ 8,677       $ 8,583  
Accounts payable       50,173         55,797  
Accrued expenses and other current liabilities       53,311         51,783  
Accrued compensation related costs       22,228         55,111  
Current portion of operating lease liabilities       33,675          
Total current liabilities       168,064         171,274  
             
Long-term liabilities:            
Long-term debt, less current portion       490,623         502,090  
Operating lease liabilities       83,693          
Other liabilities       40,259         51,570  
Total liabilities       782,639         724,934  
             
Shareholders' deficit:            
Common stock       374         371  
Additional paid-in capital       343,591         343,955  
Accumulated other comprehensive loss       (7,461 )       (4,531 )
Accumulated deficit       (366,413 )       (361,023 )
Treasury stock, at cost       (696 )       (696 )
Total shareholders' deficit       (30,605 )       (21,924 )
Total liabilities and shareholders' deficit     $ 752,034       $ 703,010  
                     
       
Table 3
Hanger, Inc.
Condensed Consolidated Statements of Cash Flows

(Unaudited - dollars in thousands)

       
     

For the Three Months
Ended March 31,

      2019     2018
Cash flow used in operating activities:            
Net loss     $ (6,951 )     $ (22,618 )
Adjustments to reconcile net loss to net cash used in operating activities:            
Depreciation and amortization       8,773         9,330  
Amortization of right-of-use assets       9,161          
Benefit for doubtful accounts       (20 )       (94 )
Stock-based compensation expense       3,265         2,585  
Deferred income taxes       (3,749 )       (6,355 )
Amortization of debt discounts and issuance costs       375         1,701  
Loss on extinguishment of debt               16,998  
Gain on sale and disposal of fixed assets       (481 )       (594 )
Changes in operating assets and liabilities:            
Accounts receivable, net       10,395         19,425  
Inventories       (880 )       1,085  
Other current assets and other assets       (1,433 )       650  
Income taxes       (355 )       12,255  
Accounts payable       (6,511 )       552  
Accrued expenses and other current liabilities       492         (5,067 )
Accrued compensation related costs       (32,970 )       (35,789 )
Other liabilities       (1,829 )       (2,537 )
Operating lease liabilities       (10,082 )        
Net cash used in operating activities       (32,800 )       (8,473 )
Cash flows used in investing activities            
Purchase of property, plant and equipment       (6,897 )       (4,388 )
Purchase of therapeutic program equipment leased to third parties under operating leases       (1,429 )       (2,034 )
Acquisitions, net of cash acquired       (27,679 )        
Purchase of company-owned life insurance investment               (598 )
Proceeds from sale of property, plant and equipment       980         840  
Net cash used in investing activities       (35,025 )       (6,180 )
Cash flows (used in) provided by financing activities            
Borrowings under term loan, net of discount               501,467  
Repayment of term loan       (1,263 )       (431,875 )
Borrowings under revolving credit agreement               3,000  
Repayments under revolving credit agreement               (8,000 )
Payment of employee taxes on stock-based compensation       (3,626 )       (2,150 )
Payment on seller notes       (1,773 )       (1,749 )
Payment of financing lease obligations       (116 )       (364 )
Payment of debt issuance costs               (6,757 )
Payment of debt extinguishment costs               (8,436 )
Net cash (used in) provided by financing activities       (6,778 )       45,136  
(Decrease) increase in cash, cash equivalents and restricted cash       (74,603 )       30,483  
Cash, cash equivalents and restricted cash, at beginning of period       95,114         4,779  
Cash, cash equivalents and restricted cash, at end of period     $ 20,511       $ 35,262  
             
Reconciliation of Cash, Cash Equivalents, and Restricted Cash:            
Cash and cash equivalents, at beginning of period     $ 95,114       $ 1,508  
Restricted cash, at beginning of period               3,271  
Cash, cash equivalents, and restricted cash, at beginning of period     $ 95,114       $ 4,779  
             
Cash and cash equivalents, at end of period     $ 20,511       $ 32,913  
Restricted cash, at end of period               2,349  
Cash, cash equivalents, and restricted cash, at end of period     $ 20,511       $ 35,262  
                     
 

Table 4

Hanger, Inc.

Segment Information: Revenue, EBITDA and Adjusted EBITDA

(Unaudited - dollars in thousands)
 

EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as operating income before certain charges, impairments of intangible assets, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, debt extinguishment costs, expenses associated with equity-based compensation, severance expenses and certain expenses incurred in connection with our acquisitions.

We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user’s understanding of normal operating income excluding certain charges, depreciation and amortization.

Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles (“GAAP”) and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

      For the Three Months Ended
March 31,
      2019     2018
             
Net Revenue (a)            
Patient Care     $ 190,601       $ 188,507  
Products & Services       45,818         45,488  
Net revenue     $ 236,419       $ 233,995  
             
EBITDA (b)            
Patient Care     $ 20,309       $ 21,991  
Products & Services       6,641         8,381  
Corporate & Other       (20,156 )       (20,419 )
EBITDA (Non-GAAP)     $ 6,794       $ 9,953  
             
Adjusted EBITDA (b)            
Patient Care     $ 21,392       $ 23,011  
Products & Services       6,885         8,651  
Corporate & Other       (16,409 )       (15,425 )
Adjusted EBITDA (Non-GAAP)     $ 11,868       $ 16,237  
(a) Excludes intersegment revenue.
(b) EBITDA and Adjusted EBITDA are "Non-GAAP" measures. Please refer to both Table 6 and Table 7 for a reconciliation of these measures to GAAP net income.
 
 
Table 5
Hanger, Inc.
Reconciliation of Net Loss and Loss Per Share to
Adjusted Net Loss and Adjusted Loss Per Share
(Unaudited - dollars in thousands, except share and per share amounts)
 

Earnings Per Share (or “EPS”) is defined as net income divided by our diluted common shares during the applicable period. Adjusted EPS is defined as EPS adjusted for impairments of intangible assets, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, debt extinguishment costs, severance expenses and certain other charges.

We utilize Adjusted EPS to assess our operating and financial performance. We believe that this measure enhances a user’s understanding of normal operating results excluding certain charges.

Adjusted EPS is not a measure of financial performance computed in accordance with GAAP and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of Adjusted EPS is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. Adjusted EPS may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

      For the Three Months Ended
March 31,
      2019     2018
             
Net loss - as reported (GAAP)     $ (6,951 )     $ (22,618 )
             
Adjustments:            
Amortization expense       1,230         1,953  
Third-party professional fees       1,649         3,700  
Loss on extinguishment of debt               16,998  
Acquisition-related expenses       170          
Severance expenses       (10 )        
Adjustments prior to tax effect     $ 3,039       $ 22,651  
             
Tax effect of specified adjustments (a)       (1,903 )       (4,717 )
Adjustments after taxes       1,136         17,934  
             
Adjusted net loss (Non-GAAP)     $ (5,815 )     $ (4,684 )
             
Basic and diluted loss per share - as reported (GAAP)     $ (0.19 )     $ (0.62 )
Effect of above listed specified adjustments       0.03         0.49  
Adjusted basic and diluted loss per share - as reported (Non-GAAP)     $ (0.16 )     $ (0.13 )
             
Shares used to compute basic and diluted loss per share       37,001,977         36,498,482  
(a) “Tax effect of specified adjustments” reflects the difference between the Company's effective provision for taxes and the application of a combined federal and state statutory tax rate of 24% and 24% respectively for the 2019 and 2018 periods to the Company's earnings from operations before taxes, after the incorporation of the identified above adjustments.
 
 
Table 6
Hanger, Inc.
Reconciliation of Net Loss to EBITDA and Adjusted EBITDA
(Unaudited - dollars in thousands)
 

EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as operating income before certain charges, impairments of intangible assets, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, debt extinguishment costs, expenses associated with equity-based compensation, severance expenses and certain expenses incurred in connection with our acquisitions.

We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user’s understanding of normal operating income excluding certain charges, depreciation and amortization.

Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles (“GAAP”) and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

      For the Three Months Ended
March 31,
      2019     2018
             
Net loss - as reported (GAAP)     $ (6,951 )     $ (22,618 )
             
Adjustments to calculate EBITDA:            
Depreciation and amortization       8,773         9,330  
Interest expense, net       8,538         12,263  
Loss on extinguishment of debt               16,998  
Non-service defined benefit plan expense       173         176  
Benefit for income taxes       (3,739 )       (6,196 )
Adjustments - net income (loss) to EBITDA       13,745         32,571  
EBITDA (Non-GAAP)       6,794         9,953  
             
Further adjustments to calculate Adjusted EBITDA:            
Third-party professional fees       1,649         3,700  
Equity-based compensation       3,265         2,584  
Acquisition-related expenses       170          
Severance expenses       (10 )        
Further adjustments - EBITDA to Adjusted EBITDA       5,074         6,284  
Adjusted EBITDA (Non-GAAP)     $ 11,868       $ 16,237  
                     
 
Table 7
Hanger, Inc.
Segment Reconciliation of (Loss) Income From Operations to EBITDA and Adjusted EBITDA
(Unaudited - dollars in thousands)
 

EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as operating income before certain charges, impairments of intangible assets, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, debt extinguishment costs, expenses associated with equity-based compensation, severance expenses and certain expenses incurred in connection with our acquisitions.

We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user’s understanding of normal operating income excluding certain charges, depreciation and amortization.

Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles (“GAAP”) and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

      For the Three Months Ended
March 31,
      2019     2018

Patient Care

           
Income from operations - as reported (GAAP)     $ 15,757       $ 17,093  
Depreciation & amortization       4,552         4,898  
EBITDA (Non-GAAP)       20,309         21,991  
Further adjustments to calculate Adjusted EBITDA:            
Equity-based compensation       1,094         1,020  
Severance expenses       (11 )        
Further adjustments - EBITDA to Adjusted EBITDA       1,083         1,020  
Adjusted EBITDA (Non-GAAP)       21,392         23,011  
             

Products & Services

           
Income from operations - as reported (GAAP)       4,098         5,879  
Depreciation & amortization       2,543         2,502  
EBITDA (Non-GAAP)       6,641         8,381  
Further adjustments to calculate Adjusted EBITDA:            
Equity-based compensation       244         270  
Severance expenses                
Further adjustments - EBITDA to Adjusted EBITDA       244         270  
Adjusted EBITDA (Non-GAAP)       6,885         8,651  
             

Corporate & Other

           
Loss from operations - as reported (GAAP)       (21,834 )       (22,349 )
Depreciation & amortization       1,678         1,930  
EBITDA (Non-GAAP)       (20,156 )       (20,419 )
Further adjustments to calculate Adjusted EBITDA:            
Third-party professional fees       1,649         3,700  
Equity-based compensation       1,927         1,294  
Acquisition related expenses       170          
Severance expenses       1          
Further adjustments - EBITDA to Adjusted EBITDA       3,747         4,994  
Adjusted EBITDA (Non-GAAP)       (16,409 )       (15,425 )
Total Adjusted EBITDA (Non-GAAP)     $ 11,868       $ 16,237  
                     
             
Table 8
Hanger, Inc.
Indebtedness

(Unaudited - dollars in thousands)

             
      As of March 31,     As of December 31,
      2019     2018
Debt:            
Term Loan B     $ 499,950       $ 501,213  
Seller notes       7,402         4,506  
Financing leases and other       1,212         14,361  
Total debt before unamortized discount and debt issuance costs       508,564         520,080  
Unamortized discount and debt issuance costs, net       (9,264 )       (9,407 )
Total debt     $ 499,300       $ 510,673  
             
Current portion of long-term debt:            
Term Loan B     $ 5,050       $ 5,050  
Seller notes       3,288         2,513  
Financing leases and other       339         1,020  
Total current portion of long-term debt       8,677         8,583  
Long-term debt:     $ 490,623       $ 502,090  
             
Net indebtedness:            
Total debt before unamortized discount and debt issuance costs       508,564         520,080  
Cash and cash equivalents       (20,511 )       (95,114 )
Net indebtedness     $ 488,053       $ 424,966  
                     
     
Table 9
Hanger, Inc.
Key Operating Metrics
     
    As of and For the
Three Months Ended
March 31,
    2019   2018
         
Same clinic revenue:        
Decline (growth) rate on net revenue   (1.6 )%   1.1 %
Growth rate day adjusted (a)   (0.1 )%   1.1 %
         
Clinical locations:        
Patient care clinics   697     683  
Satellite clinics   104     108  
Total clinical locations   801     791  
(a) Same Clinic Revenue per Day - Same Clinic Revenue per Day normalizes sales for the number of days a clinic was open in each comparable period. These measures are both non-GAAP and unaudited.
 

 

Contacts

Thomas Kiraly, Executive Vice President and Chief Financial Officer, Hanger, Inc.
512-777-3600
tkiraly@hanger.com

Seth Frank, Vice President, Treasury and Investor Relations, Hanger, Inc.
512-777-3573
sfrank@hanger.com

 
 

Source: Hanger, Inc.

MORE ON THIS TOPIC